Baysient LLC’s Post

💊 Dexamethasone and Direct Oral Anticoagulants: What Impact? 🤔 Dexamethasone is a key treatment for severe forms of COVID-19, but it could theoretically interact with direct oral anticoagulants such as apixaban and rivaroxaban, increasing the risk of thrombosis. 🚨 Our PBPK-based simulation published in the official journal of the American Society for Clinical Pharmacology & Therapeutics: Clinical Pharmacology & Therapeutics have shown that dexamethasone has possibly a limited impact on these medications in a worst-case scenario. 🤓✅ The results also suggest that prednisone could be an interesting alternative, with fewer induction effects. 🤝 Therefore, this study adding to the limited available literature suggest that the combined use of these anticoagulants and dexamethasone could be feasible in certain cases, particularly for patients at low thrombotic risk. 🩺⚕️ Thanks to all the coauthors Caroline Samer Youssef Daali Kenza Abouir, PhD Frédéric Gaspar ASCPT Journal Family https://lnkd.in/eMWStXfY #COVID19 #Pharmacology #Anticoagulants #Dexamethasone #Medicine

With nearly 5000 full-text downloads, “Rifampin Drug-Drug Interaction Studies: Reflections on the Nitrosamine Impurities Issue,” published in Clinical Pharmacology & Therapeutics in 2022, received recognition from the American Society for Clinical Pharmacology and Therapeutics as a top-ranked published article. The article explores alternative CYP3A inducers in lieu of rifampin for DDI studies. Read the paper and check all our rifampin–nitrosamine resources: https://lnkd.in/gUzDHVcS  https://lnkd.in/gSn_Thmt #TopDownloadedArticle #DrugDrugInteraction #RifampinAlternatives

💊 Unveiling the Pharmacology of Protein Synthesis Inhibitors 🧬 In the field of pharmacology, protein synthesis inhibitors play a pivotal role in therapeutic interventions. Understanding their pharmacological profiles helps in optimizing their use for treating infections and cancer. 🌟As a Health Care Professional, knowledge of their pharmacology aids in optimizing dosing regimens, minimizing side effects, and improving patient outcomes. As research advances, the pharmacological understanding of protein synthesis inhibitors will continue to enhance their therapeutic potential. #Pharmacology #ProteinSynthesisInhibitors #Antibiotics #DrugDevelopment #PharmaResearch #Healthcare

This recent study investigated which factors are associated with receiving pharmacogenetically targeted drugs, and estimated cost-effects of untargeted pre-emptive pharmacogenetic panel testing with a cost–benefit model. Published in Clinical Pharmacology & Therapeutics. https://hubs.ly/Q02ZBjHb0 | #Pharmacogenetics #PrecisionMedicine #CostBenefitModel Kaisa Litonius University of Helsinki Noora Kulla Turun yliopisto - University of Turku American Society for Clinical Pharmacology & Therapeutics

🔔 Join us at Biogen | MIT | Novartis | Whitehead Institute vendor show! We’re thrilled to be at the Biogen | MIT | Novartis | Whitehead Institute Vendor Show tomorrow! Join us and discover how our 100% guaranteed services can elevate your drug discovery projects. Explore our cutting-edge humanized mouse models, disease models, and pharmacology services. Let's connect and discuss how we can support your research! #Biogen #MIT #Novartis #WhiteheadInstitute #VendorShow #Biocytogen #DrugDiscovery #Pharmacology #HumanizedMouseModels #BiotechInnovation #ResearchCollaboration #CuttingEdgeScience

Despite PGx testing being instituted into standard clinical workflows, genotype-guided recommendations are not being adopted by all prescribers during treatment. To change standard of care, professional society clinical practice guidelines would need to endorse these recommendations; however, there has been hesitancy to do so without prospective randomized controlled trial data. How do we demonstrate evidence for implementation in cases where randomized controlled trials are not practical? Published in Clinical Pharmacology & Therapeutics. https://hubs.ly/Q02QDLqb0 | #PrecisionMedicine #PGx #Pharmacogenomics #Pharmacology Indiana University School of Medicine

Design and optimization strategies of PROTACs and its Application, Comparisons to other targeted protein degradation for multiple oncology therapies Highlights # A comprehensive chemico-biological review on proximity pharmacology induced medicinal chemistry strategies of PROTACs. # Overview on challenges, viewpoints, and most current research results of PROTACs technology. # Discusses about the possible benefits and comparision with other targeted protein degraders (LYTACs, AUTOTACs). https://lnkd.in/gn7QQ3Gk

IMRX’s VP of Clinical Pharmacology, Jan de Jong, presented interim Phase 1 pharmacokinetic & pharmacodynamic data on IMM-1-104, a novel oral Deep Cyclic Inhibitor of the MAPK pathway, at the 2024 ACoP Conference. These PK/PD modeling data, combined with Phase 1 safety and activity data, suggest that 240 mg and 320 mg are viable doses to promote Deep Cyclic Inhibition of the MAPK pathway. Learn more about our pipeline here: https://buff.ly/3hL4Z5r #RASMutations #UniversalRAS #MAPKPathway #SolidTumors #DrugDiscovery #CancerResearch #TargetedOncology #MetastaticCancer #AdvancedCancer

Really excited to announce that a paper Ken Abrams, Lawrence Wichlinski, Nancy Cullen and I wrote was published in Pharmacology, Biochemistry and Behavior! The article evaluates and ranks panic-inducing biochemical challenge procedures for lab use in the testing of novel anxiolytics. It may be of interest to anyone curious about panic disorder, pharmacological drug development, psychophysiology, and/or clinical research methods. You can read it here (free for the next ~45 days): https://lnkd.in/gwrXjmFd

Immunomodulators are miracle drugs for cancer, but they do come with risks. Health and Environmental Sciences Institute (HESI) sponsors important safety and toxicology research to recommend guidelines. This paper is one of many that this incredible organization puts out. Join HESI!